CARsgen Closes Series A To Take Cancer Immunotherapy To Clinic

Published: Nov 26, 2014

CARsgen, a Shanghai company developing cancer immunotherapies, completed a Series A funding of an undisclosed amount led by BVCF. CARsgen is developing Chimeric Antigen Receptors T (CAR-T) immunotherapies for a variety of cancers, and it plans to begin a clinical trial of its lead molecule in patients with liver cancer. BVCF (formerly BioVeda) is a China healthcare private equity investor; it closed a new $188 million fund in April.

Help employers find you! Check out all the jobs and post your resume.

Back to news